Interestingly, the two drugs both strongly affected eight inflammation-related signaling pathways: chemokine signaling, cytokine-cytokine receptor interaction, MAPK signaling, IL-17 signaling, NOD-like receptor signaling, TGF-beta signaling, TNF signaling, and pathways in cancer (Figure 8A, the intersection of the orange box and green box). This evidence concerns the gene IL17A and cancer.